Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases
BALTIMORE, March 7, 2022 — Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The partnership will leverage Elixirgen Therapeutics’ proprietary ZSCAN4 therapy platform to […]